BiotechTube

Artemether-lumefantrine

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Plasmodium Falciparum Malaria

Conditions

Plasmodium Falciparum Malaria

Trial Timeline

Jul 1, 2002 → Feb 1, 2003

NCT ID
NCT00709969

About Artemether-lumefantrine

Artemether-lumefantrine is a phase 3 stage product being developed by Novartis for Plasmodium Falciparum Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT00709969. Target conditions include Plasmodium Falciparum Malaria.

What happened to similar drugs?

0 of 1 similar drugs in Plasmodium Falciparum Malaria were approved

Approved (0) Terminated (0) Active (1)
🔄KLU156 + CoartemNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00386763Phase 3Completed
NCT00386750ApprovedTerminated
NCT00709969Phase 3Completed

Competing Products

13 competing products in Plasmodium Falciparum Malaria

See all competitors
ProductCompanyStageHype Score
KLU156 + CoartemNovartisPhase 3
40
artemether:lumefantrine (2.5 mg:30 mg)NovartisPhase 2/3
30
INE963NovartisPhase 2
35
KAE609 + Piperaquine PhosphateNovartisPhase 1
21
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
35
KAF156 + Coartem + Lumefantrine Solid Dispersion FormulationNovartisPhase 2
35
INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156NovartisPhase 2
42
KAF156 + LUM-SDF + CoartemNovartisPhase 2
35
Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/ChloroquinePfizerPhase 2/3
38
Ferroquine (SSR97193) + Placebo + artesunateSanofiPhase 2
27
Ferroquine SSR97193 + ArtefenomelSanofiPhase 2
27
Artefenomel (OZ439) + Ferroquine (SSR97193)SanofiPhase 2
35
Meplazumab for Injection + Sterile normal saline (0.9%)Pacific BiosciencesPhase 1
11